Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index–Multimedia Version (ASI-MV)

• Published in: Pain medicine (Malden, Mass.) Mass.), 2020-09, Vol.21 (9), p.1891-1901
• Main Authors: Vosburg, Suzanne K, Beaumont, Jared, Dailey-Govoni, S Taryn, Butler, Stephen F, Green, Jody L
• Format: Article
• Language: English
• Subjects: Addictions; Analgesia; Analgesics, Opioid - therapeutic use; Complications and side effects; Controlled release; Controlled release preparations; Delayed-Action Preparations; Dosage and administration; Drug abuse; Drugs; Humans; Medication abuse; Multimedia; Narcotics; Norepinephrine; Opioid receptors (type mu); Opioid-Related Disorders - drug therapy; Opioid-Related Disorders - epidemiology; PAIN & SUBSTANCE USE DISORDERS; Pain perception; Prevalence; Risk factors; Statistics; Tapentadol; United States; Vigilance
• ISSN: 1526-2375; 1526-4637
• DOI: 10.1093/pm/pnz250

Abstract Background Tapentadol is a molecule incorporating mu opioid receptor agonism and norepinephrine reuptake inhibition to provide analgesia, with the potential for a lower incidence of gastrointestinal side effects than full mu opioid agonists. Postmarketing surveillance of tapentadol as an active pharmaceutical ingredient has consistently revealed low levels of abuse and diversion. Objective The purpose of the present study was to further characterize the abuse liability of tapentadol extended-release (ER) by evaluating the prevalence of past 30-day tapentadol ER abuse and reported routes of administration as compared with ER opioids with Food and Drug Administration (FDA) abuse-deterrent labeling (“ADF opioids”) and ER opioids without FDA abuse-deterrent labeling (“non-ADF opioids”). Methods Data were collected from January 2014 through December 2017 from 776 centers located in 43 states throughout the United States using the Addiction Severity Index–Multimedia Version (ASI-MV), an instrument that is integral to the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO, Inflexxion, an IBH Company, Costa Mesa, CA, USA). Results Tapentadol ER had lower rates of past 30-day abuse than ADF ER and non-ADF ER opioid comparators, both at a population level and when adjusted for drug utilization. Tapentadol ER was primarily abused orally, although it was also abused through alternate routes of administration. Cumulative rates of tapentadol ER abuse by alternative routes of administration were lower than both ADF and non-ADF ER opioid comparators, although large confidence intervals resulting from the small sample size of reported tapentadol ER use limit firm conclusions. Conclusions In summary, tapentadol ER was found to have lower rates of both past 30-day abuse and use via alternate routes of administration, specifically snorting and smoking, than ADF and non-ADF ER comparators.